[go: up one dir, main page]

CN104870470A - 人松驰素类似物、其药物组合物及其在医药上的应用 - Google Patents

人松驰素类似物、其药物组合物及其在医药上的应用 Download PDF

Info

Publication number
CN104870470A
CN104870470A CN201480003657.1A CN201480003657A CN104870470A CN 104870470 A CN104870470 A CN 104870470A CN 201480003657 A CN201480003657 A CN 201480003657A CN 104870470 A CN104870470 A CN 104870470A
Authority
CN
China
Prior art keywords
same
human relaxin
pharmaceutical
relaxin analogue
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480003657.1A
Other languages
English (en)
Other versions
CN104870470B (zh
Inventor
张连山
刘佳建
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruishi Biomedical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201480003657.1A priority Critical patent/CN104870470B/zh
Publication of CN104870470A publication Critical patent/CN104870470A/zh
Application granted granted Critical
Publication of CN104870470B publication Critical patent/CN104870470B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明涉及人松驰素类似物、编码所述人松驰素类似物的多核苷酸、其药物组合物及其在医药上的应用，还公开了所述人松驰素类似物的衍生物。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201480003657.1A 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用 Active CN104870470B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003657.1A CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310548221 2013-11-07
CN2013105482218 2013-11-07
CN201480003657.1A CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用
PCT/CN2014/088280 WO2015067113A1 (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN104870470A true CN104870470A (zh) 2015-08-26
CN104870470B CN104870470B (zh) 2017-10-10

Family

ID=53040882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480003657.1A Active CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Country Status (13)

Country Link
US (1) US20160326230A1 (zh)
EP (1) EP3067365A1 (zh)
JP (1) JP2016536306A (zh)
KR (1) KR20160071472A (zh)
CN (1) CN104870470B (zh)
AU (1) AU2014346141A1 (zh)
BR (1) BR112016009572A2 (zh)
CA (1) CA2928754A1 (zh)
HK (1) HK1211594A1 (zh)
MX (1) MX2016005545A (zh)
RU (1) RU2016117959A (zh)
TW (1) TW201518319A (zh)
WO (1) WO2015067113A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417787B (zh) * 2016-05-23 2020-11-17 江苏恒瑞医药股份有限公司 一种人松弛素2类似物的制备方法
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
BR112019016139A2 (pt) * 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20250009454A (ko) 2022-05-07 2025-01-17 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CN102180964A (zh) * 2011-03-16 2011-09-14 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的固相合成方法
CN102603888A (zh) * 2012-04-11 2012-07-25 郭德军 一种人松弛素2前体及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CN102180964A (zh) * 2011-03-16 2011-09-14 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的固相合成方法
CN102603888A (zh) * 2012-04-11 2012-07-25 郭德军 一种人松弛素2前体及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法

Also Published As

Publication number Publication date
JP2016536306A (ja) 2016-11-24
TW201518319A (zh) 2015-05-16
MX2016005545A (es) 2016-10-03
CA2928754A1 (en) 2015-05-14
US20160326230A1 (en) 2016-11-10
BR112016009572A2 (pt) 2017-09-19
KR20160071472A (ko) 2016-06-21
HK1211594A1 (zh) 2016-05-27
CN104870470B (zh) 2017-10-10
EP3067365A1 (en) 2016-09-14
AU2014346141A1 (en) 2016-05-19
RU2016117959A (ru) 2017-12-11
WO2015067113A1 (zh) 2015-05-14

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
WO2016011222A3 (en) Circular polynucleotides
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
WO2016011306A3 (en) Terminal modifications of polynucleotides
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CN105829298A (zh) 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
TWD179715S (zh) 房間之部分
JP2017537928A5 (zh)
CN110366425A (zh) 一种预防动脉粥样硬化及其并发症的方法
CN104870470A (zh) 人松驰素类似物、其药物组合物及其在医药上的应用
LT3399978T (lt) Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas
HUE046033T2 (hu) Új kriptoficin vegyületek és konjugátumok, elõállításuk és gyógyászati alkalmazásuk
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
EP3818144C0 (en) AQUEOUS TOPICAL COMPOSITIONS CONTAINING VIABLE PROBIOTIC BACTERIA
CN106687453A8 (zh) 作为溴结构域抑制剂的四氢喹啉衍生物
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
MX374245B (es) Derivados de naftiridinadiona.
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211594

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200110

Address after: 201210 Room 201 and 203, floor 2, building 1, No. 298, Xiangke Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Ruishi biomedical Co., Ltd

Address before: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Co-patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov.

Patentee before: Hengrui Pharmaceutical Co., Ltd., Shanghai

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211594

Country of ref document: HK